[1] Hatswell AJ, Baio G, Berlin JA, et al. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. BMJ open 2016;6:e011666 10.1136/bmjopen-2016-011666 [27363818]

[2] Downing NS, Aminawung JA, Shah ND, et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 2014;311:368–77 10.1001/jama.2013.282034 [24449315]

[3] Bours MJL. A nontechnical explanation of the counterfactual definition of confounding. J Clin Epidemiol 2020;121:91–100 10.1016/j.jclinepi.2020.01.021 [32068101]

[4] International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. CHOICE OF CONTROL GROUP AND RELATED ISSUES IN CLINICAL TRIALS E10.


[6] Glassman RH, Kim G, Kahn MJ. When are results of single-arm studies dramatic? Nat Rev Clin Oncol 2020;17:651–52 10.1038/s41571-020-00429-1 [32859976]

[7] Tang H, Foster NR, Grothey A, et al. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. JCO 2010;28:1936–41 10.1200/JCO.2009.25.5489 [20212253]

[8] Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020;382:2327–36 10.1056/NEJMoa2007016 [32275812]

[9] Rittberg R, Czaykowski P, Niraula S. Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies. JNCI Cancer Spectrum 2021;5:pkab061 10.1093/jncics/pkab061 [34409254]

[10] Kanter J, Walters MC, Krishnamurti L, et al. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. N Engl J Med 2022;386:617–28 10.1056/NEJMoa2117175 [34898139]

[11] Tennant PWG, Arnold KF, Ellison GTH, et al. Analyses of 'change scores'do not estimate causal effects in observational data. Int J Epidemiol 2021 10.1093/ije/dyab050 [34100077]

[12] Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med 2022;386:1013–25 10.1056/NEJMoa2113708 [35294811]

[13] FDA/CDER/mccrayk. Rare Diseases: Common Issues in Drug Development: Guidance for Industry ;

[14] International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Choice of control group and related issues in clinical trials E10 2000.

[15] Suissa S. Single-arm trials with historical controls: Study designs to avoid time-related biases. Epidemiology 2020 10.1097/EDE.0000000000001267 [33009252]

[16] Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. The Lancet 2016;387:1909–20 10.1016/S0140-6736(16)00561-4

[17] Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. The Lancet 2018;391:748–57 10.1016/S0140-6736(17)33297-X [29268948]

[18] Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 2012;15:940–47 10.1016/j.jval.2012.05.004 [22999145]

[19] Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. PharmacoEconomics 2010;28:935–45 10.2165/11538370-000000000-00000 [20831302]

[20] Fox MP, Lash TL. On the Need for Quantitative Bias Analysis in the Peer-Review Process. Am J Epidemiol 2017;185:865–68 10.1093/aje/kwx057 [28430833]

[21] Lash TL, Fox MP, Cooney D, et al. Quantitative Bias Analysis in Regulatory Settings. Am J Public Health 2016;106:1227–30 10.2105/AJPH.2016.303199 [27196652]

[22] Lash TL, Fox MP, MacLehose RF, et al. Good practices for quantitative bias analysis. Int J Epidemiol 2014;43:1969–85 10.1093/ije/dyu149 [25080530]

[23] David M. Phillippo, A. E. Ades, Sofia Dias, Stephen Palmer, Keith R. Abrams, Nicky J. Welton. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE 2016.

[24] Sridhara R, Mandrekar SJ, Dodd LE. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials. Clin Cancer Res 2013;19:2613–20 10.1158/1078-0432.CCR-12-2938 [23669421]

[25] Denne JS, Stone AM, Bailey-Iacona R, et al. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials. Journal of biopharmaceutical statistics 2013;23:951–70 10.1080/10543406.2013.813515 [23957509]

[26] Marks HM. A rational therapeutics: Science and the reform of therapeutics in the United States, 1900-1990. Cambridge England, New York: Cambridge University Press 1997 ISBN:0521581427;

[27] Debray TPA, Damen JAAG, Snell KIE, et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ 2017;356:i6460 10.1136/bmj.i6460 [28057641]

[28] Carrigan G, Whipple S, Capra WB, et al. Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled Trials. Clin Pharmacol Ther 2020;107:369–77 10.1002/cpt.1586 [31350853]

[29] Larrouquere L, Giai J, Cracowski J-L, et al. Externally Controlled Trials: Are We There Yet? Clin Pharmacol Ther 2020;108:918–19 10.1002/cpt.1881 [32542679]

[30] Ribeiro TB, Colunga-Lozano LE, Araujo APV, et al. Single-arm clinical trials that supported FDA Accelerated Approvals have modest effect sizes and at high risk of bias. Journal of Clinical Epidemiology 2022 10.1016/j.jclinepi.2022.01.018 [35093531]